Sickle Cell Disease Treatment Market Worth $4.69 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
08 nov. 2023 02h53 HE
|
The Insight Partners
Pune, India, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sickle cell disease (SCD) is the most common inherited blood disorder that affects the red blood cells. Treatments for SCD can relieve pain and help...
Sickle Cell Consortium Hosts 6th Annual Leadership Summit - Advocacy & Capacity-Building in the Digital Age
25 avr. 2022 08h00 HE
|
Sickle Cell Consortium
ATLANTA, April 25, 2022 (GLOBE NEWSWIRE) -- The Sickle Cell Consortium hosts the 6th Annual Leadership Summit and General Assembly of Patients, Caregivers, and Community-Based Organizations (CBOs)...
Hydroxyurea-based treatment for sickle cell anemia previously available for pediatric patients now approved for use in adults
16 févr. 2022 07h00 HE
|
Medunik USA
ROSEMONT, PA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Medunik USA is pleased to announce that Siklos® (hydroxyurea), previously indicated to reduce the frequency of painful crises and to reduce the need...
Sickle Cell Disease Market in North America to Surpass US$ 2,200.5 Million by 2028, Says Coherent Market Insights (CMI)
16 juil. 2021 08h40 HE
|
CMI
SEATTLE, July 16, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the North America sickle cell disease market is estimated to be valued at US$ 770.5 Million in 2021 and is expected...
Prenatal and New-born Genetic Testing Market revenue to cross USD 9.5 Bn by 2027: Global Market Insights Inc.
07 juil. 2021 05h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, July 07, 2021 (GLOBE NEWSWIRE) -- According to latest report “Prenatal and New-born Genetic Testing Market by Technology (Screening, Diagnostic), Disease (Downs Syndrome,...
Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price
12 juil. 2012 09h15 HE
|
Vista Partners
SAN FRANCISCO, CA--(Marketwire - Jul 12, 2012) - Vista Partners announced today that it has updated coverage on ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) (NYSE Amex: ANX) ("The Company,"...
HemaQuest Pharmaceuticals Receives European Orphan Medicinal Product Designations for Therapeutic to Treat Hemoglobin Disorders
26 mars 2009 12h54 HE
|
HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - March 26, 2009) - HemaQuest Pharmaceuticals today announced that
it has received two orphan medicinal product designations from the European
Commission for its product...
HemaQuest Pharmaceuticals Announces Clinical Progress on New Sickle Cell Anemia Drug
09 déc. 2008 12h01 HE
|
HemaQuest Pharmaceuticals
SAN FRANCISCO, CA--(Marketwire - December 9, 2008) - HemaQuest Pharmaceuticals announced
today the successful completion of Phase 1 clinical trials of HQK-1001, an
orally-administered therapeutic...